ArticleNeurodegenerative disease management2014
Aberrant RNA homeostasis in amyotrophic lateral sclerosis: potential for new therapeutic targets?
Article in Neurodegenerative disease management, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Globally reduced NNature neuroscience · 2023Article
- Disrupting pathologic phase transitions in neurodegeneration.The Journal of clinical investigation · 2023Review
- A mark of disease: how mRNA modifications shape genetic and acquired pathologies.RNA (New York, N.Y.) · 2021Review
- RNA-recognition motif in Matrin-3 mediates neurodegeneration through interaction with hnRNPM.Acta neuropathologica communications · 2020Article
- Amyotrophic Lateral Sclerosis and its Mimics/Variants: A Comprehensive Review.Journal of clinical imaging science · 2018Review
- Role of Extracellular Vesicles in Amyotrophic Lateral Sclerosis.Frontiers in neuroscience · 2018Review
- Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders.Molecular neurobiology · 2017Review
- Unraveling the Role of RNA Mediated Toxicity ofFrontiers in neuroscience · 2017Review
- C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.Scientific reports · 2016Article
- Rosmarinic Acid Alleviates Neurological Symptoms in the G93A-SOD1 Transgenic Mouse Model of Amyotrophic Lateral Sclerosis.Experimental neurobiology · 2015Article
- From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive motor neuron degeneration. The disease pathogenesis is multifaceted in that multiple cellular and molecular pathways have been identified as contributors to the disease progression. Consequently, numerous therapeutic targets have been pursued for clinical development, unfortunately with little success. The recent discovery of mutations in RNA modulating genes such as TARDBP/TDP-43, FUS/TLS or C9ORF72 changed our understanding of neurodegenerative mechanisms in ALS and introduced the role of dysfunctional RNA processing as a significant contributor to disease pathogenesis. This article discusses the latest findings on such RNA toxicity pathways in ALS and potential novel therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.